Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease

Abstract Background Gut-directed hypnosis (GDH) is a complimentary therapy for Inflammatory Bowel Disease (IBD), that can be learnt by patients to practice self-hypnosis. GDH in IBD has augmented remission and improved inflammation. GDH has a history of successful use for Irritable Bowel Syndrome (IBS). In IBD it may also improve IBS-like symptoms in remission and recovery from surgery. GDH is suitable for youth and adult IBD patients. In hypnosis, a relaxed state is inducted then suggestions to subconscious mind processes are made. In IBD, the mechanism of action of GDH is unknown but may influence the disease stress response. Aims Aims are the development of a GDH self-hypnosis protocol for IBD, with appropriate target symptoms. Patients first learn to practice with a clinician, then as complimentary psychotherapy for remission augmentation, IBS-like symptoms, and surgery recovery. Methods GDH is practiced first with a clinician, and then by patients as self-hypnosis (table 1). Patients receive psycho-education on GDH for IBD. Next, appropriate treatment goals are made, based on target symptoms. Relaxation techniques induce patient to a deeply relaxed state. Therapeutic suggestions specific to patient goals are given: verbal suggestions, visualizations, and post-hypnotic suggestions. Suggestions can focus on having a healthy digestive system, inflammation and symptoms reduction, and achievement and sustainment of remission. Patients emerge from hypnosis, are debriefed, and encouraged to practice ongoing self-hypnosis. Results In IBD, GDH self-hypnosis can be learnt from clinicians and practiced by patients as a complimentary therapy. Patients’ achievement and sustainment of remission, with clinical markers of inflammation can be monitored. Patients can monitor subjective improvement of IBS-like symptoms and post surgery, recovery progress can be monitored. Conclusions GDH has a history of use for IBS. In IBD, it has been shown to modulate remission, and may improve IBS-like symptoms, and in surgery recovery. The mechanism of action of GDH in IBD may influence the disease stress response. Clinicians trained in GDH are limited currently. Patients may learn GDH self- hypnosis to as a complimentary psychotherapy.

Download Full-text

Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2009.04057.x ◽

2009 ◽

Vol 30 (4) ◽

pp. 375-384 ◽

Cited By ~ 63

Author(s):

M. A. SMITH ◽

A. M. MARINAKI ◽

M. ARENAS ◽

M. SHOBOWALE-BAKRE ◽

C. M. LEWIS ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Treatment Outcome ◽

Bowel Disease ◽

Inflammatory Bowel

Download Full-text

(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review

Molecules ◽

10.3390/molecules26071843 ◽

2021 ◽

Vol 26 (7) ◽

pp. 1843

Author(s):

Marilyn Hagan ◽

Bu' Hussain Hayee ◽

Ana Rodriguez-Mateos

Keyword(s):

Inflammatory Bowel Disease ◽

Irritable Bowel Syndrome ◽

Bowel Disease ◽

Evidence Base ◽

Therapeutic Benefit ◽

Markers Of Inflammation ◽

Related Quality ◽

Health Related ◽

Inflammatory Bowel ◽

Irritable Bowel

(Poly)phenols (PPs) may have a therapeutic benefit in gastrointestinal (GI) disorders, such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). The aim of this review is to summarise the evidence-base in this regard. Observational evidence does not give a clear indication that PP intake has a preventative role for IBD or IBS, while interventional studies suggest these compounds may confer symptomatic and health-related quality of life improvements in known patients. There are inconsistent results for effects on markers of inflammation, but there are promising reports of endoscopic improvement. Work on the effects of PPs on intestinal permeability and oxidative stress is limited and therefore conclusions cannot be formed. Future work on the use of PPs in IBD and IBS will strengthen the understanding of clinical and mechanistic effects.

Download Full-text

Fecal markers in the management of inflammatory bowel disease

Postgraduate Medicine ◽

10.1080/00325481.2018.1503919 ◽

2018 ◽

Vol 130 (7) ◽

pp. 597-606 ◽

Cited By ~ 2

Author(s):

Cong Dai ◽

Min Jiang ◽

Ming-Jun Sun

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Fecal Markers ◽

Inflammatory Bowel

Download Full-text

Circulating CD4+and CD8+T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation

Immunology ◽

10.1111/imm.12114 ◽

2013 ◽

Vol 140 (1) ◽

pp. 87-97 ◽

Cited By ~ 72

Author(s):

Nicholas T. Funderburg ◽

Samantha R. Stubblefield Park ◽

Hannah C. Sung ◽

Gareth Hardy ◽

Brian Clagett ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

T Cells ◽

Cd8 T Cells ◽

Bowel Disease ◽

Markers Of Inflammation ◽

Inflammatory Bowel ◽

Plasma Markers

Download Full-text

Finding the Right Index for Inflammatory Bowel Disease

Canadian Journal of Gastroenterology ◽

10.1155/1995/696385 ◽

1995 ◽

Vol 9 (7) ◽

pp. 397-400

Author(s):

E Jan Irvine

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Subjective Symptoms ◽

Markers Of Inflammation ◽

Laboratory Markers ◽

Study Population ◽

Inflammatory Bowel ◽

The Right ◽

Activity Indices ◽

The Ideal

Several activity indices have been developed to assess the efficacy of new therapies for inflammatory bowel disease. The ideal index should be simple to administer and quantitative. It should be a composite of subjective symptoms, objective findings and laboratory markers of inflammation. Any newly developed indices should be assessed for validity, reliability and responsiveness before application in clinical trials. Obstacles to standardizing disease activity relate to the heterogeneity of disease manifestations, the characteristics of the study population, the therapy being tested, the investigators' preference for which index to apply and the attributes of the index. Examples of available indices are identified, some of their limitations are discussed, and guidelines for how to select an index for a clinical trial are outlined.

Download Full-text